Chiesi Farmaceutici S.p.a.

This study tested two doses of an inhaled drug called CHF6001 (Tanimilast) in people with COPD and chronic bronchitis who were already on standard triple therapy. The goal was to see if adding this drug could reduce moderate or severe flare-ups over a year. The trial was stopped …

This study tested an experimental inhaler (CHF6001) added to standard asthma medicines in 517 adults with uncontrolled asthma. The goal was to see if it could reduce severe asthma attacks over 52 weeks. However, the trial was terminated early, so results are limited.

This study tested whether adding an experimental inhaler (CHF6001) to standard triple therapy could reduce flare-ups in people with severe COPD and chronic bronchitis. About 4,000 adults aged 40 and older who were current or former smokers and had at least one flare-up in the pas…